At the Mayo Clinic, Dr. Guifang Zhao is leading a new generation of regenerative medicine therapies that combine the ...

The "Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century--A Risk Based Approach" initiative was ...

Researchers uncovered a previously unknown CRISPR immune response in bacteria that targets transfer RNAs. The newly ...

A novel CRISPR defense mechanism, unlike known nucleases, specifically destroys transfer ribonucleic acids (tRNA) that are ...

Lead program UKK-0018 for peanut allergy has received regulatory clearance in AU and NZ to begin clinical trials in 1H 2026Expands leadership with appointment of Grace Chen-Philips, M.D., as Chief ...

Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax ...

In a surprising discovery, University of New Mexico researchers have found that OTULIN – an enzyme that helps regulate the immune system – also drives ...

Knowable Magazine reports 2025 faced turmoil in U.S. science amid job cuts and budget slashes, yet saw advances in gene ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

The "Biological Therapies for Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

BioNTech's financial results provide a baseline for the enlarged entity post-CureVac integration. In the third quarter of 2025, the company generated approximately €1.5 billion in revenue and ...

Following the completion of the share exchange offer in December, BioNTech swiftly moved to acquire the remaining outstanding shares, achieving full integration of CureVac's business operations.